Janney Montgomery Scott LLC Takes Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Janney Montgomery Scott LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,827 shares of the company’s stock, valued at approximately $239,000.

A number of other institutional investors and hedge funds have also modified their holdings of TMDX. Harbour Capital Advisors LLC grew its position in TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after acquiring an additional 81 shares during the period. Venturi Wealth Management LLC grew its position in TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares during the period. National Bank of Canada FI grew its position in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares during the period. Quarry LP grew its position in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the period. Finally, Farther Finance Advisors LLC grew its position in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Trading Up 2.1 %

Shares of TMDX opened at $69.52 on Thursday. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a market capitalization of $2.33 billion, a PE ratio of 73.96 and a beta of 2.12. The stock’s fifty day simple moving average is $65.75 and its 200-day simple moving average is $107.98.

Insider Activity

In other news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Canaccord Genuity Group reduced their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Finally, Robert W. Baird reduced their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.